biotech / news / / The Manila Times
Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembroluxumab alone.
Cylembio plus pembrolizumab achieved 19.4 months mPFS versus 11.0 months with pembrolizumab alone.
KEY POINTS
- The trial narrowly missed PFS primary endpoint statistical significance with a p-value of 0.0558.
- Combination therapy improved PFS across PD-L1-negative, BRAFV600-mutated, and elevated LDH subgroups without added systemic toxicity.
- Post-hoc analysis excluding prior anti-PD-1 therapy showed mPFS of 24.8 vs 11.0 months.
- Phase 2 basket trial showed durable responses in NSCLC and SCCHN with no new safety signals.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →